Evidence map›Paper›PMID 39841442›Full record

ArticleJAMA2025

Polygenic Risk Score Added to Conventional Case Finding to Identify Undiagnosed Chronic Obstructive Pulmonary Disease.

Jingzhou Zhang, Brian D Hobbs, Edwin K Silverman, David Sparrow, Victor E Ortega, Hanfei Xu, Chengyue Zhang, Josée Dupuis, Allan J Walkey, George T O'Connor and 2 more

Abstract readEvaluation Study
In one paragraph

Article in JAMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Polygenic risk scores in the clinic: Health-system leaders and primary care providers weigh in.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Towards early detection and disease interception of COPD across the lifespan.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingzhou ZhangThe Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Brian D HobbsChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Edwin K SilvermanChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
David SparrowThe Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Victor E OrtegaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
Hanfei XuDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Chengyue ZhangChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Josée DupuisDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Allan J WalkeyDivision of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts.
George T O'ConnorThe Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Michael H ChoChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Matthew MollChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Respiratory Computational Discovery CoreP01HL114501 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHOI, MARY E · 2013 to 2025
$24.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
(2 of 2) Genetic Epidemiology of COPDR01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2012 to 2016
$18.9M
Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7M
COPD Susceptibility, Heterogeneity, and Progression: Proteomics and GeneticsR01HL133135 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORITZ, ROBERT L, SILVERMAN, EDWIN K · 2017 to 2025
$7.2M
Leveraging Variant-perturbed Gene Regulation to Support Precision Medicine in COPDR01HL155749 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Kimberly Renee Glass · 2022 to 2026
$4.2M
Genetic and Functional Dissection of a Cluster of COPD GWAS Signals on Chromosome 4qR01HL147148 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHO, MICHAEL H., SILVERMAN, EDWIN K · 2019 to 2022
$3.5M
Identifying Protein-Protein Network Interactions between COPD Susceptibility GenesR01HL152728 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K, WEI, WENYI · 2021 to 2024
$3.2M
Uncovering the genetically-driven differential susceptibility to chronic obstructive pulmonary disease and pulmonary fibrosisR01HL162813 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO · 2023 to 2026
$3.1M
Hepatocyte Growth Factor Signaling and Airspace MaintenanceR01HL160008 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEPTUNE, ENID R · 2021 to 2024
$3.0M
Integrative genomic, transcriptomic and proteomic studies of pulmonary function and COPDR01HL153248 · NHLBI · UNIVERSITY OF VIRGINIA · PI CHO, MICHAEL H., MANICHAIKUL, ANI WANG · 2021 to 2024
$2.8M
NHLBI NIH HHS K08 HL159318NHLBI NIH HHS P01 HL114501NHLBI NIH HHS R01 HL089856NHLBI NIH HHS R01 HL133135NHLBI NIH HHS R01 HL135142NHLBI NIH HHS R01 HL147148NHLBI NIH HHS R01 HL152728NHLBI NIH HHS R01 HL153248NHLBI NIH HHS R01 HL155749NHLBI NIH HHS R01 HL160008NHLBI NIH HHS R01 HL162813NHLBI NIH HHS R01 HL168199NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897
6 · The paper itself

Abstract

Importance: Chronic obstructive pulmonary disease (COPD) is often undiagnosed. Although genetic risk plays a significant role in COPD susceptibility, its utility in guiding spirometry testing and identifying undiagnosed cases is unclear. Objective: To determine whether a COPD polygenic risk score (PRS) enhances the identification of undiagnosed COPD beyond a case-finding questionnaire (eg, the Lung Function Questionnaire) using conventional risk factors and respiratory symptoms. Design, Setting, and Participants: This cross-sectional analysis of participants 35 years or older who reported no history of physician-diagnosed COPD was conducted using data from 2 observational studies: the community-based Framingham Heart Study (FHS) and the COPD-enriched Genetic Epidemiology of COPD (COPDGene) study. Exposures: Modified Lung Function Questionnaire (mLFQ) scores and COPD PRS. Main Outcomes and Measures: The primary outcome was spirometry-defined moderate to severe COPD (forced expiratory volume in the first second of expiration/forced vital capacity [FEV1/FVC] <0.7 and FEV1 [percent predicted] <80%). The performance of logistic models was assessed using the PRS, mLFQ score, and PRS plus mLFQ score for predicting spirometry-defined COPD. Results: Among 3385 FHS participants (median age, 52.0 years; 45.9% male) and 4095 COPDGene participants (median age, 56.8 years; 55.5% male) who reported no history of COPD, 160 (4.7%) FHS and 775 (18.9%) COPDGene participants had spirometry-defined COPD. Adding the PRS to the mLFQ score significantly improved the area under the curve from 0.78 to 0.84 (P < .001) in FHS, 0.69 to 0.72 (P = .04) in COPDGene non-Hispanic African American, and 0.75 to 0.78 (P < .001) in COPDGene non-Hispanic White participants. At a risk threshold for spirometry referral of 10%, the addition of the PRS to the mLFQ score correctly reclassified 13.8% (95% CI, 6.6%-21.0%) of COPD cases in FHS, but not in COPDGene. Conclusions and Relevance: A COPD PRS enhances the identification of undiagnosed COPD beyond a conventional case-finding approach in the general population. Further research is needed to assess its impact on COPD diagnosis and outcomes.

Indexed as

Genetic Risk ScoreMultifactorial InheritancePulmonary Disease, Chronic ObstructiveAdultAgedAged, 80 and overBlack or African AmericanCross-Sectional StudiesFemaleForced Expiratory VolumeHumansLogistic ModelsMaleMassachusettsMiddle AgedMulticenter Studies as Topic

Identifiers

PMID39841442
PMCPMC11880956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.